Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review - PubMed
6 hours ago
- #Alzheimer's disease
- #neurotherapeutic agents
- #cost-effectiveness
- The study reviews the cost-effectiveness of FDA-approved neurotherapeutic agents for Alzheimer's disease (AD).
- Traditional drugs like memantine, donepezil, rivastigmine, and galantamine were found cost-effective at a $100,000/QALY threshold.
- Newer anti-amyloid therapies (aducanumab, lecanemab, donanemab) were not cost-effective at standard thresholds.
- Value-based pricing suggests much lower prices for anti-amyloid drugs to be cost-effective.
- Most studies used QALY as the effectiveness measure and Markov models for analysis.
- Industry-funded studies accounted for 43%, while non-profits funded 39%.
- The review highlights the need for independent analyses and real-world data comparisons.